Literature DB >> 20478521

Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers.

Yu Chen1, Charles L Sawyers.   

Abstract

In this issue of Cancer Cell, Yu and colleagues mapped the genomic binding sites of ERG and androgen receptor, two crucial transcription factors in prostate cancer. There is an extraordinary degree of overlap between binding sites, with the suggestion that ERG inhibits androgen receptor-mediated differentiation and promotes EZH2-mediated dedifferentiation. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Year:  2010        PMID： 20478521      PMCID： PMC2931314          DOI： 10.1016/j.ccr.2010.04.022

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance.

Authors:  Jeff Holzbeierlein; Priti Lal; Eva LaTulippe; Alex Smith; Jaya Satagopan; Liying Zhang; Charles Ryan; Steve Smith; Howard Scher; Peter Scardino; Victor Reuter; William L Gerald
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

2.  FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

Authors:  Mathieu Lupien; Jérôme Eeckhoute; Clifford A Meyer; Qianben Wang; Yong Zhang; Wei Li; Jason S Carroll; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2008-03-21       Impact factor: 41.582

3.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

Authors:  Howard I Scher; Tomasz M Beer; Celestia S Higano; Aseem Anand; Mary-Ellen Taplin; Eleni Efstathiou; Dana Rathkopf; Julia Shelkey; Evan Y Yu; Joshi Alumkal; David Hung; Mohammad Hirmand; Lynn Seely; Michael J Morris; Daniel C Danila; John Humm; Steve Larson; Martin Fleisher; Charles L Sawyers
Journal:  Lancet       Date:  2010-04-14       Impact factor: 79.321

4.  An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.

Authors:  Junxia Min; Alexander Zaslavsky; Giuseppe Fedele; Sara K McLaughlin; Elizabeth E Reczek; Thomas De Raedt; Isil Guney; David E Strochlic; Laura E Macconaill; Rameen Beroukhim; Roderick T Bronson; Sandra Ryeom; William C Hahn; Massimo Loda; Karen Cichowski
Journal:  Nat Med       Date:  2010-02-14       Impact factor: 53.440

5.  Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.

Authors:  Sook Shin; Tae-Dong Kim; Fang Jin; Jan M van Deursen; Scott M Dehm; Donald J Tindall; Joseph P Grande; Jan-Marie Munz; George Vasmatzis; Ralf Janknecht
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

6.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

7.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

8.  DNA specificity determinants associate with distinct transcription factor functions.

Authors:  Peter C Hollenhorst; Katherine J Chandler; Rachel L Poulsen; W Evan Johnson; Nancy A Speck; Barbara J Graves
Journal:  PLoS Genet       Date:  2009-12-18       Impact factor: 5.917

9.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

Authors:  Jennifer C King; Jin Xu; John Wongvipat; Haley Hieronymus; Brett S Carver; David H Leung; Barry S Taylor; Chris Sander; Robert D Cardiff; Suzana S Couto; William L Gerald; Charles L Sawyers
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

10.  New androgen receptor genomic targets show an interaction with the ETS1 transcription factor.

Authors:  Charles E Massie; Boris Adryan; Nuno L Barbosa-Morais; Andy G Lynch; Maxine G Tran; David E Neal; Ian G Mills
Journal:  EMBO Rep       Date:  2007-08-17       Impact factor: 8.807
  10 in total
  7 in total

Review 1.  TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.

Authors:  Cindy Ke Zhou; Denise Young; Edward D Yeboah; Sally B Coburn; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Shelley Niwa; Ann Truelove; Judith Welsh; James E Mensah; Robert N Hoover; Isabell A Sesterhenn; Ann W Hsing; Shiv Srivastava; Michael B Cook
Journal:  Am J Epidemiol       Date:  2017-12-15       Impact factor: 4.897

2.  A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Authors:  Kern Rei Chng; Cheng Wei Chang; Si Kee Tan; Chong Yang; Shu Zhen Hong; Noel Yan Wei Sng; Edwin Cheung
Journal:  EMBO J       Date:  2012-04-24       Impact factor: 11.598

Review 3.  Recurrent gene fusions in prostate cancer: their clinical implications and uses.

Authors:  Daphne Hessels; Jack A Schalken
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

4.  Independence of HIF1a and androgen signaling pathways in prostate cancer.

Authors:  Maxine G B Tran; Becky A S Bibby; Lingjian Yang; Franklin Lo; Anne Y Warren; Deepa Shukla; Michelle Osborne; James Hadfield; Thomas Carroll; Rory Stark; Helen Scott; Antonio Ramos-Montoya; Charlie Massie; Patrick Maxwell; Catharine M L West; Ian G Mills; David E Neal
Journal:  BMC Cancer       Date:  2020-05-25       Impact factor: 4.430

5.  Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.

Authors:  G Schaefer; J-M Mosquera; R Ramoner; K Park; A Romanel; E Steiner; W Horninger; J Bektic; M Ladurner-Rennau; M A Rubin; F Demichelis; H Klocker
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-02-05       Impact factor: 5.554

6.  Modeling the Mechanism of GR/c-Jun/Erg Crosstalk in Apoptosis of Acute Lymphoblastic Leukemia.

Authors:  Daphne Wei-Chen Chen; Marija Krstic-Demonacos; Jean-Marc Schwartz
Journal:  Front Physiol       Date:  2012-11-19       Impact factor: 4.566

7.  Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide.

Authors:  Giorgia Urbinati; Isabelle de Waziers; Mateja Slamiç; Tobias Foussignière; Hafiz M Ali; Didier Desmaële; Patrick Couvreur; Liliane Massaad-Massade
Journal:  Mol Ther Nucleic Acids       Date:  2016-03-29       Impact factor: 10.183
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.